ES2056832T3 - Un vehiculo de liberacion para un ingrediente activo. - Google Patents

Un vehiculo de liberacion para un ingrediente activo.

Info

Publication number
ES2056832T3
ES2056832T3 ES87311040T ES87311040T ES2056832T3 ES 2056832 T3 ES2056832 T3 ES 2056832T3 ES 87311040 T ES87311040 T ES 87311040T ES 87311040 T ES87311040 T ES 87311040T ES 2056832 T3 ES2056832 T3 ES 2056832T3
Authority
ES
Spain
Prior art keywords
active ingredient
release vehicle
delivery
biocompatible
delivery vehicles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87311040T
Other languages
English (en)
Other versions
ES2056832T5 (es
Inventor
Crispin George Stewart Eley
Paul Gardner Schmidt
Gary Fujii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexstar Pharmaceuticals Inc
Original Assignee
Vestar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25477566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2056832(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vestar Inc filed Critical Vestar Inc
Publication of ES2056832T3 publication Critical patent/ES2056832T3/es
Application granted granted Critical
Publication of ES2056832T5 publication Critical patent/ES2056832T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02M—APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF
    • H02M1/00—Details of apparatus for conversion
    • H02M1/08—Circuits specially adapted for the generation of control voltages for semiconductor devices incorporated in static converters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02M—APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF
    • H02M1/00—Details of apparatus for conversion
    • H02M1/06—Circuits specially adapted for rendering non-conductive gas discharge tubes or equivalent semiconductor devices, e.g. thyratrons, thyristors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Power Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Electronic Switches (AREA)

Abstract

SE DESCRIBEN VEHICULOS DE LIBERACION QUE COMPRENDEN UNA CAPA ENCAPSULANTE BIOCOMPATIBLE, UNA CAPA ASOCIADA A UN PRINCIPIO ACTIVO ANFIFILICO INTERNA Y UN PRINCIPIO ACTIVO. LOS VEHICULOS DE LIBERACION SON BIOCOMPATIBLES Y CAPACES DE SOLUBILIZAR EL PRINCIPIO PARA LIBERACION EN VIVO A TEJIDOS Y OTROS SISTEMAS CORPOREOS. LOS USOS INCLUYEN FORMACION DE IMAGEN EN RMN Y COMO MEDICAMENTO TERAPEUTICO.
ES87311040T 1986-12-15 1987-12-15 Vehiculo para la liberacion que contiene un agente activo asociado con una substancia anfifila. Expired - Lifetime ES2056832T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94209386A 1986-12-15 1986-12-15

Publications (2)

Publication Number Publication Date
ES2056832T3 true ES2056832T3 (es) 1994-10-16
ES2056832T5 ES2056832T5 (es) 1999-04-16

Family

ID=25477566

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87311040T Expired - Lifetime ES2056832T5 (es) 1986-12-15 1987-12-15 Vehiculo para la liberacion que contiene un agente activo asociado con una substancia anfifila.

Country Status (11)

Country Link
EP (1) EP0272091B2 (es)
JP (1) JP2677572B2 (es)
KR (2) KR950015052B1 (es)
AT (1) ATE89717T1 (es)
AU (1) AU608264B2 (es)
CA (1) CA1319614C (es)
DE (1) DE3786005T3 (es)
DK (1) DK175531B1 (es)
ES (1) ES2056832T5 (es)
IE (1) IE60562B1 (es)
NO (1) NO171583C (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043107A (en) * 1986-08-21 1991-08-27 Vestar Research, Inc. Preparation small unilamellar vesicles including polyene antifungal antibiotics
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
JPH04501723A (ja) * 1988-11-09 1992-03-26 アンガー，エヴァン，シー． リポソーム性放射線造影剤
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5705187A (en) 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5352435A (en) 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
WO1992005773A1 (en) * 1990-10-09 1992-04-16 Vestar, Inc. Phospholipid analogue vesicle with a succinimidyl moiety
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
AU6832794A (en) * 1993-05-19 1994-12-12 Liposome Company, Inc., The Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
US5736121A (en) 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US5630786A (en) * 1994-06-27 1997-05-20 Ionix Corporation Boron neutron capture enhancement of fast neutron therapy
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
DE19500665A1 (de) * 1995-01-12 1996-07-18 Axel Prof Dr Haase Verfahren zur ortsauflösenden Abbildung eines Bereiches eines biologischen Objektes mit Hilfe elektromagnetischer Strahlen unter Applikation von Kontrastmittel
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
CA2234957C (en) 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
DE69736981D1 (de) 1996-05-01 2007-01-04 Imarx Pharmaceutical Corp In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
ATE366588T1 (de) 1996-09-11 2007-08-15 Imarx Pharmaceutical Corp Verfahren zur diagnostischen bilderzeugung der nierenregion unter verwendung eines kontrastmittels und eines vasodilators
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
FR2754828B1 (fr) * 1996-10-23 1998-12-24 Univ Toulouse Structure membranaire artificielle, procede et polymere pour sa preparation, procede de preparation de ce polymere, particule et film comprenant cette structure
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
JP2002516267A (ja) 1998-05-29 2002-06-04 アールティーピー・ファーマ・インコーポレーテッド 熱的に保護された微粒子組成物及びその最終蒸気滅菌
EE05190B1 (et) 1998-11-20 2009-08-17 Rtp Pharma Inc. Dispergeeruvad fosfolipiididega stabiliseeritud mikroosakesed
CA2407027C (en) 2000-04-20 2011-02-15 Rtp Pharma Inc. Improved water-insoluble drug particle process
DE60137943D1 (de) 2000-08-31 2009-04-23 Jagotec Ag Gemahlene partikel
DE10331439B3 (de) 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
KR20070052747A (ko) * 2004-09-10 2007-05-22 도레이 가부시끼가이샤 의약품제제
AU2007336297B2 (en) 2006-12-18 2013-09-05 Colorobbia Italia S.P.A. Magnetic nanoparticles for the application in hyperthermia, preparation thereof and use in constructs having a pharmacological application
US10022459B2 (en) * 2011-06-13 2018-07-17 National University Corporation Chiba University Medical tissue-marker and manufacturing method for the same
JP6482604B2 (ja) * 2017-06-22 2019-03-13 教裕 南郷 外皮内溶解型ニードル及びニードル装置
CN110455848B (zh) * 2018-05-08 2024-02-23 国家纳米科学中心 基于络合反应放大信号的铁离子纵向弛豫时间传感器及其构建方法、用途
EP3714879A1 (en) * 2019-03-28 2020-09-30 Sisaf Ltd Structured encapsulated silicon-containing particles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208294A (en) * 1979-02-12 1980-06-17 The United States Of America, As Represented By The Secretary Of The Interior Dilution stable water based magnetic fluids
PT81498B (pt) * 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
EP0198765A3 (en) * 1985-04-09 1987-10-21 Georgetown University Preparation of liposomes
US5041581A (en) * 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes

Also Published As

Publication number Publication date
NO171583B (no) 1992-12-28
IE60562B1 (en) 1994-07-27
KR880008502A (ko) 1988-08-31
ATE89717T1 (de) 1993-06-15
NO171583C (no) 1993-04-07
EP0272091A3 (en) 1988-10-12
KR950015052B1 (ko) 1995-12-21
EP0272091B2 (en) 1998-10-28
DK651187D0 (da) 1987-12-11
DK175531B1 (da) 2004-11-22
EP0272091B1 (en) 1993-05-26
DK651187A (da) 1988-06-16
NO875194D0 (no) 1987-12-14
CA1319614C (en) 1993-06-29
DE3786005T3 (de) 1999-04-01
NO875194L (no) 1988-06-16
KR880007065A (ko) 1988-08-26
AU608264B2 (en) 1991-03-28
ES2056832T5 (es) 1999-04-16
EP0272091A2 (en) 1988-06-22
DE3786005T2 (de) 1993-09-02
DE3786005D1 (de) 1993-07-01
JPS63233915A (ja) 1988-09-29
AU8249487A (en) 1988-06-16
IE873387L (en) 1988-06-15
JP2677572B2 (ja) 1997-11-17

Similar Documents

Publication Publication Date Title
ES2056832T3 (es) Un vehiculo de liberacion para un ingrediente activo.
AU1627588A (en) Biodadhesion drug carriers for endothelial and epithelial uptake and lesional localization of therapeutic and diagnostic agents
HU9602356D0 (en) Drug targeting system, method for preparing same and its use
DE69111821D1 (de) In einem nichtwässrigen perfluorierten trägermedium suspendierte wirkstoffabgabevehikel.
EP1125577A3 (en) Liquid drug delivery compositions
US4649075A (en) Transdermal and transmucosal vortexed foam devices and the method of making
DE69732760D1 (de) Intravaginal-ringe mit einsetzbarem medikamentenenthaltenden kern
UY23665A1 (es) Procedimiento para la preparacion de compuesto farmaceutico
DE69925936D1 (de) Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle
CA2214503A1 (en) Method for treating tumors
ATE99544T1 (de) Liposomale radiologische kontrastmittel.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
HUP0003840A2 (hu) Szabályozott hatóanyagleadású gyógyászati készítmények
Luck et al. Phase I study of weekly docetaxel (Taxotere (R)) in heavily pretreated breast cancer patients
EP1325753A3 (en) Bio-compatible means for controlled drug delivery to tissue and method of use
WO2002094199A3 (en) METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD
GR3032224T3 (en) Therapeutic agent for threatened abortion.
Vick et al. External beam radiotherapy: hard facts and painful realities
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
FR2786699B1 (fr) Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
Alyautdin et al. Drug targeting system, method for preparing same and its use
Levy et al. Iliac angioplasty. American College of Radiology. ACR Appropriateness Criteria
Norkus et al. Patton ML, Simone MR, Kraut JD, Anderson HL 111, Haig LR, jr Burns, 24: 566-8, 1998
Levanon et al. Cerebrovascular tight junctions in rats exposed to O2 toxicity